Upcoming Events

DateTitle
Jun. 05, 2017
Juno Therapeutics at the 2017 American Society of Clinical Oncology Annual Meeting

Past Events

DateTitle
05/16/17 3:40 p.m. PT
Juno Therapeutics at Bank of America Merrill Lynch 2017 Health Care Conference
2017 | 2016 | 2015 | 2014 | 2013
 

DateTitle 
May. 23, 2017Juno Therapeutics Appoints Jay Flatley to Board of Directors
SEATTLE--(BUSINESS WIRE)--May 23, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed Jay Flatley to its Board of Directors. Mr. Flatley is Executive Chairman of Illumina, Inc. A successful entrepreneur, Mr. Flatley brings to Juno’s board his considerable experience building a highly successful and innovative ... 
Printer Friendly Version
May. 17, 2017Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 and JCAR014 at the 2017 American Society of Clinical Oncology Annual Meeting
SEATTLE--(BUSINESS WIRE)--May 17, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that it will present key clinical updates in partnership with its collaborators on its investigational products JCAR017 and JCAR014 at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2017 in Chicago, Illinois, June 2-6. ... 
Printer Friendly Version
May. 09, 2017Juno Therapeutics to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
SEATTLE--(BUSINESS WIRE)--May 9, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Bank of America Merrill Lynch 2017 Health Care Conference at 3:40 p.m. PT on Tuesday, May 16, 2017. The presentation will feature a business overview and update by Steve Harr, Juno’s Chief Financial Officer and Head of Corporate Development. The webcast will be accessible on the Investor Relations page of Jun... 
Printer Friendly Version
May. 04, 2017Juno Therapeutics Reports First Quarter 2017 Financial Results
– Initiated five trials with new binders, technologies, and targets – – 2017 cash burn and operating burn guidance reaffirmed – – Added key talent to leadership team – – Eleven product candidates in clinical trials against eight different targets – – Strong cash position of $850.7 million – – Conference call today at 5:00 p.m. Eastern Time – SEATTLE--(BUSINESS WIRE)--May 4, 2017-- Juno Therapeutic... 
Printer Friendly Version
Apr. 27, 2017Juno Therapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4
SEATTLE--(BUSINESS WIRE)--Apr. 27, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the first quarter 2017 on Thursday, May 4, 2017, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern Time (ET). Analysts... 
Printer Friendly Version
Apr. 19, 2017Juno Therapeutics Appoints Rupert Vessey to Board of Directors
SEATTLE--(BUSINESS WIRE)--Apr. 19, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed to its Board of Directors Dr. Rupert Vessey, President of Research and Early Development of Celgene Corporation. Dr. Vessey brings significant drug development capabilities to the Juno Board. Before joining Celgene in Januar... 
Printer Friendly Version
Apr. 17, 2017Juno Therapeutics Appoints Sunil Agarwal as President of Research and Development
Experienced executive addition with proven leadership and drug development expertise in emerging fields of medicine SEATTLE--(BUSINESS WIRE)--Apr. 17, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed Sunil Agarwal, M.D., as President of Research and Development. With Dr. Agarwal’s appointment, Juno will bring R... 
Printer Friendly Version
Mar. 01, 2017Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results
– Nine product candidates in clinical trials against eight different targets – – Pivotal trial for JCAR017 in r/r DLBCL expected to start in 2017 – – Phase I JCAR017 demonstrates 80% overall response and 60% complete response in r/r DLBCL – – Discontinuing development of JCAR015 in r/r adult ALL to focus on defined cell product in this setting – – 2016 year end cash position of $922.3 million – – 2017... 
Printer Friendly Version
Feb. 28, 2017Juno Therapeutics to Present at March 2017 Investor Conferences
SEATTLE--(BUSINESS WIRE)--Feb. 28, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update. Hans Bishop, Juno’s President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference at 10:40 a.m. ET on Tuesday, March 7, 2017. ... 
Printer Friendly Version
Feb. 22, 2017Juno Therapeutics to Report Full Year and Fourth Quarter 2016 Financial Results on Wednesday, March 1
SEATTLE--(BUSINESS WIRE)--Feb. 22, 2017-- Juno Therapeutics, Inc. (NASDAQ:JUNO) will announce financial results for the fourth quarter and year ended December 31, 2016, on Wednesday, March 1, 2017, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern ... 
Printer Friendly Version
Jan. 27, 2017Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
Experienced executive brings demonstrated operational excellence to Juno, will lead newly formed group focused on development operations SEATTLE--(BUSINESS WIRE)--Jan. 27, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the appointment of Corsee D. Sanders, Ph.D., as Executive Vice President and Head of Development Operations, effect... 
Printer Friendly Version
Jan. 03, 2017Juno Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Jan. 3, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the 35th Annual J.P. Morgan Healthcare Conference at 4:30 p.m. PT on Tuesday, January 10, 2017. The presentation will feature a business overview and update by Hans Bishop, Juno’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Juno's website at www.... 
Printer Friendly Version